This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
1cP-LSD: Difference between revisions
>Unity m Removed protection from "1cP-LSD" |
>Discount Pharmacologist Chemistry and pharmacology info added |
||
| Line 17: | Line 17: | ||
1cP-LSD is a semisynthetic compound of the [[lysergamide]] family. It is similar to [[LSD]] and is named for the cyclopropionyl group bound to the nitrogen of the polycyclic indole group of LSD. The cyclopropionyl group consists of a carbonyl ring with the chemical formula C<sub>3</sub>H<sub>6</sub> bound to an amino group. | 1cP-LSD is a semisynthetic compound of the [[lysergamide]] family. It is similar to [[LSD]] and is named for the cyclopropionyl group bound to the nitrogen of the polycyclic indole group of LSD. The cyclopropionyl group consists of a carbonyl ring with the chemical formula C<sub>3</sub>H<sub>6</sub> bound to an amino group. | ||
The structure of 1cP-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group. At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound. | The structure of 1cP-LSD contains a polycyclic group featuring a bicyclic hexahydro indole bound to a bicyclic quinoline group. At carbon 8 of the quinoline, an N,N-diethyl carboxamide is bound. | ||
The properties of the substance 1cP-LSD are described as almost identical to those of the classic LSD 25 and 1P-LSD. However, an alkylcarbonyl group has the empirical formula C4H7O, whereas the cyclopropylcarbonyl group corresponds to a molecular formula of C4H5O. Accordingly, one can not call the cyclopropyl as alkyl radical and thus the substance 1cP-LSD is not affected by the NpSG amending Regulation.<ref>https://rcreviewsin.com/new-lysergamide-1cp-lsd/</ref> | |||
==Pharmacology== | ==Pharmacology== | ||
| Line 23: | Line 25: | ||
Based on its structural similarity to LSD, 1cP-LSD likely acts as a [[Agonist#Agonists|partial agonist]] at the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] receptor. | Based on its structural similarity to LSD, 1cP-LSD likely acts as a [[Agonist#Agonists|partial agonist]] at the [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] receptor. | ||
The [[psychedelic]] effects are thought to primarily come from its efficacy at the 5-HT<sub>2A</sub> receptors distributed throughout the brain. 1cP-LSD also likely displays binding activity at a wide range of [[monoamine]] receptors, such as those for [[dopamine]] and [[norepinephrine]]. However, there is currently no data to support these claims. | The [[psychedelic]] effects are thought to primarily come from its efficacy at the 5-HT<sub>2A</sub> receptors distributed throughout the brain. 1cP-LSD also likely displays binding activity at a wide range of [[monoamine]] receptors, such as those for [[dopamine]] and [[norepinephrine]]. However, there is currently no data to support these claims. | ||
Most serotonergic psychedelics are not significantly dopaminergic, and 1-cP-LSD is therefore atypical in this regard. The agonism of the D<sub>2</sub> receptor may contribute to its psychoactive effects in humans.<ref>Marona-Lewicka D, Thisted RA, Nichols DE (July 2005). "Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis". ''Psychopharmacology''. '''180''' (3): 427–35. doi:10.1007/s00213-005-2183-9. <nowiki>PMID 15723230</nowiki>. S2CID 23565306.</ref> 1cP-LSD binds to most serotonin receptor subtypes except for the 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors. However, most of these receptors are affected at too low affinity to be sufficiently activated by the brain concentration of approximately 10–20 nM.<ref>Nichols DE (February 2004). "Hallucinogens". ''Pharmacology & Therapeutics''. '''101''' (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. <nowiki>PMID 14761703</nowiki>.</ref> Recreational doses can affect 5-HT<sub>1A</sub> (K<sub>i</sub>=1.1nM), 5-HT<sub>2A</sub> (K<sub>i</sub>=2.9nM), 5-HT<sub>2B</sub> (K<sub>i</sub>=4.9nM), 5-HT<sub>2C</sub> (K<sub>i</sub>=23nM), 5-HT<sub>5A</sub> (K<sub>i</sub>=9nM [in cloned rat tissues]), and 5-HT<sub>6</sub> receptors (K<sub>i</sub>=2.3nM). | |||
1cP-LSD is a biased agonist that induces a conformation in serotonin receptors that preferentially recruits β-arrestin over activating G proteins.<ref>Chen Q, Tesmer JJ (January 2017). "A Receptor on Acid". ''Cell''. '''168''' (3): 339–341. doi:10.1016/j.cell.2017.01.012. PMC 5520807. <nowiki>PMID 28129534</nowiki>.</ref> A crystal structure of 5-HT<sub>2B</sub> bound to 1cP-LSD reveals an extracellular loop that forms a lid over the diethylamide end of the binding cavity which explains the slow rate of unbinding from serotonin receptors.<ref>UNC Health Care (January 26, 2017). "This is LSD Attached to a Brain Cell Serotonin Receptor (Update)". ''Phys.org''.</ref> | |||
==Subjective effects== | ==Subjective effects== | ||
| Line 146: | Line 152: | ||
{{#ask: [[Category:1cP-LSD]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:1cP-LSD]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_SUBSTANCE.shtml Erowid Experience Vaults: SUBSTANCE] <!-- Check the link to see if it exists --> | |||
*[https://www.erowid.org/experiences/subs/exp_SUBSTANCE.shtml Erowid Experience Vaults: SUBSTANCE]<!-- Check the link to see if it exists --> | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 173: | Line 180: | ||
==Legal status== | ==Legal status== | ||
{{LegalStub}} | {{LegalStub}} | ||
*'''Germany''': 1cP-LSD is not a controlled substance under the BtMG (''Narcotics Act'')<ref>{{cite web|title=Betäubungsmittelgesetz (BtMG)|trans-title=Narcotics Act (BtMG)|url=http://www.gesetze-im-internet.de/btmg_1981/BtMG.pdf|publisher=Bundesamt für Justiz [Federal Office of Justice]|language=de|access-date=July 14, 2020|date=July 28, 1981}}</ref> or the NpSG (''New Psychoactive Substances Act'').<ref>{{cite web|title=Neue-psychoaktive-Stoffe-Gesetz (NpSG)|trans-title=New Psychoactive Substances Act (NpSG)|url=https://www.gesetze-im-internet.de/npsg/NpSG.pdf|date=November 21, 2016|access-date=July 14, 2020|publisher=Bundesamt für Justiz [Federal Office of Justice]|language=de}}</ref> It is legal, as long as it is not sold for human consumption, according to §2 AMG.<ref>{{cite web|title=§2 Arzneimittelgesetz (AMG)|trans-title=§2 Pharmaceutical Act (AMG)|url=https://www.gesetze-im-internet.de/amg_1976/__2.html|language=de|access-date=July 14, 2020 | |||
*'''Germany''': 1cP-LSD is not a controlled substance under the BtMG (''Narcotics Act'')<ref>{{cite web|title=Betäubungsmittelgesetz (BtMG)|trans-title=Narcotics Act (BtMG)|url=http://www.gesetze-im-internet.de/btmg_1981/BtMG.pdf|publisher=Bundesamt für Justiz [Federal Office of Justice]|language=de|access-date=July 14, 2020|date=July 28, 1981}}</ref> or the NpSG (''New Psychoactive Substances Act'').<ref>{{cite web|title=Neue-psychoaktive-Stoffe-Gesetz (NpSG)|trans-title=New Psychoactive Substances Act (NpSG)|url=https://www.gesetze-im-internet.de/npsg/NpSG.pdf|date=November 21, 2016|access-date=July 14, 2020|publisher=Bundesamt für Justiz [Federal Office of Justice]|language=de}}</ref> It is legal, as long as it is not sold for human consumption, according to §2 AMG.<ref>{{cite web|title=§2 Arzneimittelgesetz (AMG)|trans-title=§2 Pharmaceutical Act (AMG)|url=https://www.gesetze-im-internet.de/amg_1976/__2.html|language=de|access-date=July 14, 2020|publisher=Bundesamt für Justiz [Federal Office of Justice]}}</ref> | |||
*'''Sweden''': Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/december/tjugotre-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/|title=Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara | trans-title = Twenty-three substances are proposed to be classified as drugs or dangerous goods |publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|language=sv|date=December 18, 2019|access-date=July 14, 2020}}</ref> | *'''Sweden''': Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on December 18, 2019.<ref>{{cite web|url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/december/tjugotre-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/|title=Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara | trans-title = Twenty-three substances are proposed to be classified as drugs or dangerous goods |publisher=Folkhälsomyndigheten [Public Health Agency of Sweden]|language=sv|date=December 18, 2019|access-date=July 14, 2020}}</ref> | ||
*'''United Kingdom''': 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|title=Psychoactive Substances Act 2016|publisher=legislation.gov.uk|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|access-date=July 14, 2020}}</ref> | *'''United Kingdom''': 1cP-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|title=Psychoactive Substances Act 2016|publisher=legislation.gov.uk|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|access-date=July 14, 2020}}</ref> | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemicals]] | *[[Research chemicals]] | ||
| Line 196: | Line 205: | ||
Please see the [[citation formatting guide]] if you need assistance properly formatting citations. | Please see the [[citation formatting guide]] if you need assistance properly formatting citations. | ||
--> | --> | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Psychoactive substance]][[Category:Proofread]][[Category:Approval]] | [[Category:Psychoactive substance]] | ||
[[Category:Proofread]] | |||
[[Category:Approval]] | |||